Show simple item record

dc.contributor.authorChidambaram, S
dc.contributor.authorKawka, M
dc.contributor.authorGall, TM
dc.contributor.authorCunningham, D
dc.contributor.authorJiao, LR
dc.coverage.spatialEngland
dc.date.accessioned2022-09-13T08:43:05Z
dc.date.available2022-09-13T08:43:05Z
dc.date.issued2022-06-22
dc.identifier.citationFuture Oncology, 2022, 18 (23), pp. 2605 - 2612
dc.identifier.issn1479-6694
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5441
dc.identifier.eissn1744-8301
dc.identifier.eissn1744-8301
dc.identifier.doi10.2217/fon-2021-1545
dc.description.abstractPancreatic ductal adenocarcinoma (PDAC) is the most prevalent malignant pancreatic tumor. Few studies have shown how often PDACs arise from cystic precursor lesions. This special report aims to summarize the evidence on the progression of precancerous lesions to PDAC. A review of the literature found four studies that discussed pancreatic intraepithelial lesions (PanINs), three that discussed mucinous cystic neoplasms (MCN) and five that discussed intraductal papillary neoplasms (IPMNs). PanINs were the most common precursors lesion, with approximately 80% of PDACs originating from this lesion. The lack of evidence characterizing the features of PDAC precursor cystic lesions potentially leads to a subset of patients undergoing surgery unnecessarily. Advancements in molecular techniques could allow the study of cystic lesions at a genetic level, leading to more personalized management.
dc.formatPrint-Electronic
dc.format.extent2605 - 2612
dc.languageeng
dc.language.isoeng
dc.publisherFUTURE MEDICINE LTD
dc.relation.ispartofFuture Oncology
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectIPMN
dc.subjectMCN
dc.subjectPDAC
dc.subjectPanIN
dc.subjectpancreatic cancer
dc.subjectpancreatic cysts
dc.subjectpersonalized medicine
dc.subjectCarcinoma, Pancreatic Ductal
dc.subjectHumans
dc.subjectPancreas
dc.subjectPancreatic Neoplasms
dc.subjectPrecancerous Conditions
dc.titleCan we predict the progression of premalignant pancreatic cystic tumors to ductal adenocarcinoma?
dc.typeJournal Article
dcterms.dateAccepted2022-06-06
dc.date.updated2022-09-13T08:42:15Z
rioxxterms.versionVoR
rioxxterms.versionofrecord10.2217/fon-2021-1545
rioxxterms.licenseref.startdate2022-06-22
rioxxterms.typeJournal Article/Review
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/35730473
pubs.issue23
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.)
pubs.publication-statusPublished
pubs.publisher-urlhttp://dx.doi.org/10.2217/fon-2021-1545
pubs.volume18
icr.researchteamMedicine (RMH)
dc.contributor.icrauthorCunningham, David
icr.provenanceDeposited by Mr Arek Surman on 2022-09-13. Deposit type is initial. No. of files: 1. Files: fon-2021-1545.pdf


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc-nd/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/